{
    "clinical_study": {
        "@rank": "61894", 
        "arm_group": [
            {
                "arm_group_label": "sildenafil, standard of care", 
                "arm_group_type": "No Intervention", 
                "description": "Infants receiving sildenafil as standard of care"
            }, 
            {
                "arm_group_label": "sildenafil administered for study", 
                "arm_group_type": "Other", 
                "description": "1 dose of sildenafil administered for study"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn more about the safety and dosing of sildenafil in\n      infants."
        }, 
        "brief_title": "Pharmacokinetics of Sildenafil in Premature Infants", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Persistent Pulmonary Hypertension of the Newborn", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary", 
                "Persistent Fetal Circulation Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Pharmacokinetics and safety of sildenafil will be studied in preterm infants who are\n      receiving sildenafil per standard of care or 1 dose prescribed for the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Cohort 1:\n\n          -  Gestational age 28 weeks or less receiving sildenafil as standard of care < 365\n             postnatal days\n\n        Cohort 2:\n\n          -  Gestational age 28 weeks or less\n\n          -  7-28 postnatal days of age\n\n          -  Mechanical ventilation or nasal continuous positive airway pressure (NCPAP) or\n             high-flow nasal cannula\n\n          -  Intravenous line in place\n\n        Exclusion Criteria:\n\n        Cohort 1:\n\n          -  Any condition that would make the participant, in the opinion of the investigator,\n             unsuitable for the study\n\n        Cohort 2:\n\n          -  Previous exposure to sildenafil within 7 days prior to enrollment\n\n          -  Any condition that would make the participant, in the opinion of the investigator,\n             unsuitable for the study\n\n          -  History of allergic reactions to sildenafil\n\n          -  AST > ULN or ALT > 3x ULN\n\n          -  Currently on a vasopressor for hypotension\n\n          -  Known sickle cell disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "364 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670136", 
            "org_study_id": "11-1646"
        }, 
        "intervention": {
            "arm_group_label": "sildenafil administered for study", 
            "description": "A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush.  Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.75 mg/kg.", 
            "intervention_name": "1 dose of sildenafil", 
            "intervention_type": "Drug", 
            "other_name": [
                "Revatio", 
                "Viagra"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "sildenafil", 
            "preterm infants", 
            "persistent pulmonary hypertension of the newborn"
        ], 
        "lastchanged_date": "March 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35249-7335"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }, 
                "investigator": {
                    "last_name": "Ambalavanan Namasivayam, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Riley Hospital"
                }, 
                "investigator": {
                    "last_name": "Shawn Ahlfeld, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "Kosair Pediatric Research Unit"
                }, 
                "investigator": {
                    "last_name": "Dan Stewart, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina"
                }, 
                "investigator": {
                    "last_name": "Sigal Peter-Wohl, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke University"
                }, 
                "investigator": {
                    "last_name": "C. Michael Cotten, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }, 
                "investigator": {
                    "last_name": "Andrew Atz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetics of Sildenafil in Premature Infants", 
        "overall_contact": {
            "email": "matt_laughon@med.unc.edu", 
            "last_name": "Matthew M Laughon, MD, MPH", 
            "phone": "919-966-5063"
        }, 
        "overall_contact_backup": {
            "email": "maurine.morris@duke.edu", 
            "last_name": "Maurine Morris", 
            "phone": "919-668-8349"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina", 
            "last_name": "Matthew M Laughon, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve 0-24 hours for sildenafil", 
                "safety_issue": "No", 
                "time_frame": "IV study dose 0-15 min,1-2,3-4,12-14,24-30,48-56hr after flush.Clinical care: IV <0.5hr before dose <15 min & 3-4hr after flush <0.5hr before next dose. Enteral <0.5hr before dose, 1-2 & 3-4hr after dose, <0.5hr before next dose.  22-26hr after last dose"
            }, 
            {
                "measure": "Peak plasma concentration of sildenafil", 
                "safety_issue": "No", 
                "time_frame": "IV study dose 0-15 min,1-2,3-4,12-14,24-30,48-56hr after flush.Clinical care: IV <0.5hr before dose <15 min & 3-4hr after flush <0.5hr before next dose. Enteral <0.5hr before dose, 1-2 & 3-4hr after dose, <0.5hr before next dose. 22-26hr after last dose"
            }, 
            {
                "measure": "Clearance of sildenafil", 
                "safety_issue": "No", 
                "time_frame": "IV study dose 0-15 min,1-2,3-4,12-14,24-30,48-56hr after flush.Clinical care: IV <0.5hr before dose <15 min & 3-4hr after flush <0.5hr before next dose. Enteral <0.5hr before dose, 1-2 & 3-4hr after dose, <0.5hr before next dose. 22-26hr after last dose"
            }, 
            {
                "measure": "Volume of distribution at steady state", 
                "safety_issue": "No", 
                "time_frame": "IV study dose 0-15 min,1-2,3-4,12-14,24-30,48-56hr after flush.Clinical care: IV <0.5hr before dose <15 min & 3-4hr after flush <0.5hr before next dose. Enteral <0.5hr before dose, 1-2 & 3-4hr after dose, <0.5hr before next dose. 22-26hr after last dose"
            }, 
            {
                "measure": "Half life of sildenafil", 
                "safety_issue": "No", 
                "time_frame": "IV study dose 0-15 min,1-2,3-4,12-14,24-30,48-56hr after flush.Clinical care: IV <0.5hr before dose <15 min & 3-4hr after flush <0.5hr before next dose. Enteral <0.5hr before dose, 1-2 & 3-4hr after dose, <0.5hr before next dose. 22-26hr after last dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670136"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects with adverse events as a measure of safety and tolerability.", 
                "safety_issue": "Yes", 
                "time_frame": "From the time of the first dose to 3 days after the last dose; serious adverse events will be collected from the first dose of sildenafil to 7 days after the last dose of sildenafil"
            }, 
            {
                "measure": "Correlation between serum and dried blood spot samples", 
                "safety_issue": "No", 
                "time_frame": "1-7 days"
            }, 
            {
                "measure": "Evaluate P450 single nucleotide polymorphisms (SNPs)", 
                "safety_issue": "No", 
                "time_frame": "2-7 days"
            }
        ], 
        "source": "University of North Carolina, Chapel Hill", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Duke University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "The EMMES Corporation", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of North Carolina, Chapel Hill", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}